- Home
- MREO
as 07-25-2025 4:00pm EST
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
| Founded: | 2015 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 438.8M | IPO Year: | N/A |
| Target Price: | $7.20 | AVG Volume (30 days): | 4.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.31 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.57 - $5.02 | Next Earning Date: | 08-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 51.92% |
Latest Mereo BioPharma Group plc News
MREO Breaking Stock News: Dive into MREO Ticker-Specific Updates for Smart Investing
Investor's Business Daily
16 days ago
Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone Disease
MT Newswires
16 days ago
Top Midday Decliners
MT Newswires
16 days ago
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading
Barrons.com
16 days ago
Biotech Stock Ultragenyx Is Falling on Unsatisfying Trial Update
MT Newswires
16 days ago
Ultragenyx Shares Drop as Osteogenesis Trial Update Disappoints Investors
MT Newswires
16 days ago
Sector Update: Health Care Stocks Mixed Premarket Thursday
MT Newswires
16 days ago
Sector Update: Health Care
MT Newswires
17 days ago
Ultragenyx, Mereo Advance Phase 3 Study of Genetic Bone Disorder Toward Final Analysis
Compare MREO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MREO Mereo BioPharma Group plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.